Evidence map›Paper›PMID 40534675›Full record

ArticleACS pharmacology & translational science2025

Mechanistic Insights of a p53-Targeting Small Molecule.

Ricardo J F Ferreira, Valentina Barcherini, Catarina Roma-Rodrigues, Miriama Sikorová, Lucília Saraiva, Ana P Leandro, Pedro V Baptista, Alexandra R Fernandes, Alexandra M M Antunes, Maria M M Santos

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ricardo J F FerreiraResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal.
Valentina BarcheriniResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal.
Catarina Roma-RodriguesAssociate Laboratory i4HBInstitute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, Caparica 2819-516, Portugal.
Miriama SikorováAssociate Laboratory i4HBInstitute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, Caparica 2819-516, Portugal.
Lucília SaraivaLAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, Porto, 4050-313, Portugal.ORCID https://orcid.org/0000-0002-9531-4939
Ana P LeandroResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal.
Pedro V BaptistaAssociate Laboratory i4HBInstitute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, Caparica 2819-516, Portugal.ORCID https://orcid.org/0000-0001-5255-7095
Alexandra R FernandesAssociate Laboratory i4HBInstitute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, Caparica 2819-516, Portugal.ORCID https://orcid.org/0000-0003-2054-4438
Alexandra M M AntunesCentro de Química Estrutural (CQE), Institute of Molecular Sciences, Departamento de Engenharia Química, Instituto Superior Técnico (IST), Universidade de Lisboa, Lisboa 1049-001, Portugal.ORCID https://orcid.org/0000-0003-1827-7369
Maria M M SantosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal.ORCID https://orcid.org/0000-0002-2239-9353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Restoring the p53 pathway, particularly by reactivating wild-type (wt) or mutant (mut) p53, is considered a promising approach for cancer treatment. Previously, we identified the tryptophanol-derived oxazoloisoindolinone family as a new scaffold for obtaining wt and mut p53 reactivators. Herein, we report a detailed study on the pharmacokinetic profile and the mechanism of action of

Indexed as

cancercysteineisoindolinonesp53protein modification

Identifiers

PMID40534675
PMCPMC12171893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.